Page last updated: 2024-08-21

2,2-dimethylbutyric acid and Gastritis

2,2-dimethylbutyric acid has been researched along with Gastritis in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT	1

Trials

1 trial(s) available for 2,2-dimethylbutyric acid and Gastritis

Article	Year
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. American journal of hematology, 2013, Volume: 88, Issue:11 Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Child; Cohort Studies; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin; Gastritis; Hematinics; Heterozygote; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Patient Dropouts; Promoter Regions, Genetic; Sickle Cell Trait; Up-Regulation; Young Adult	2013

Article

Year

A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.

American journal of hematology, 2013, Volume: 88, Issue:11

Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Child; Cohort Studies; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin; Gastritis; Hematinics; Heterozygote; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Patient Dropouts; Promoter Regions, Genetic; Sickle Cell Trait; Up-Regulation; Young Adult

2013